Marc Judson is a Respiratory physician. OpenAlex indexes 459 publications with 27,039 citations (h-index 79); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
16 New Scotland Ave
Albany, NY 122083504
Telephone
518-262-4458Provider last certified this registry record 5 Mar 2026.
Clinical trials
- ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial
Sponsor: Albany Medical College
- ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study
Sponsor: Albany Medical College
- Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Sponsor: Medical University of South Carolina
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20252 payments
- Merck Sharp & Dohme LLCProgram year20247 payments
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
45.4%Corticosteroid45.4%Prednisone100%Part D≥64 patientsCancer & immunology
30.1%Folate Analog Metabolic Inhibitor16.4%Methotrexate100%Part D≥26 patientsTNF inhibitor11.3%Humira(Cf) Pen33%Inflectra25%Remicade24%Humira Pen18%Part D<11 patients+ 1 more class in this area
Respiratory
17.5%Corticosteroid10.9%Trelegy Ellipta53%Budesonide-Formoterol Fumarate27%Breo Ellipta20%Part D<11 patientsbeta2-Adrenergic Agonist4.7%Albuterol Sulfate Hfa100%Part D≥16 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline
American Journal of Respiratory and Critical Care Medicine
2020
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”